CircRNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145

Han, Yang; Zhao, Min; Li, Zhao; Li, Ping; Duan, Yuxia; Li, Gang

doi:10.1007/s13402-020-00503-x

Cited by 43 publications

(39 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reported 13 , A549 cells (at 6 × 10 5 cells per dish) were re-suspended in 0.5% agar-containing complete medium and added on top of a pre-solidified cell culture dishes. GDC-0349-containing medium was replenished every two days (total five rounds).…”

Section: Colony Formation Assaymentioning

confidence: 99%

“…As reported 13,16 , NSCLC cells (in serum free medium, 4 × 10,000 cells per chamber) were seeded at the upper surfaces of "Transwell" chambers (BD Biosciences, Heidelberg, Germany). The lower compartments were filled with FBS-containing complete medium.…”

Section: Cell Migration and Invasion Assaysmentioning

confidence: 99%

“…The detailed protocols for apoptosis assays, including TUNEL staining, Annexin V-propidium iodide (PI) FACS, and caspase-3/-9 activity assays were described in detail in our previous studies 13,17,18 .…”

Section: Apoptosis Assaysmentioning

confidence: 99%

See 2 more Smart Citations

GDC-0349 inhibits non-small cell lung cancer cell growth

Han

Zhao

et al. 2020

Cell Death Dis

Self Cite

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related human mortality with a clear need for new therapeutic intervention. GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor. In A549 cells and primary human NSCLC cells, GDC-0349 inhibited cell growth, proliferation, cell cycle progression, migration and invasion, while inducing significant apoptosis activation. Although GDC-0349 blocked Akt-mTORC1/2 activation in NSCLC cells, it also exerted cytotoxicity in Akt1-knockout A549 cells. Furthermore, restoring Akt-mTOR activation by a constitutively-active Akt1 only partially attenuated GDC-0349-induced A549 cell apoptosis, indicating the existence of Akt-mTOR-independent mechanisms. In NSCLC cells GDC-0349 induced sphingosine kinase 1 (SphK1) inhibition, ceramide accumulation, JNK activation and oxidative injury. Conversely, N-acetylcysteine, the JNK inhibitor and sphingosine 1-phosphate alleviated GDC-0349-induced NSCLC cell apoptosis. In vivo, daily oral administration of GDC-0349 potently inhibited NSCLC xenograft growth in mice. Akt-mTOR in-activation, SphK1 inhibition, JNK activation and oxidative stress were detected in NSCLC xenograft tissues with GDC-0349 administration. In summary, GDC-0349 inhibits NSCLC cell growth via Akt-mTOR-dependent and Akt-mTOR-independent mechanisms.

show abstract

Section: Colony Formation Assaymentioning

confidence: 99%

Section: Cell Migration and Invasion Assaysmentioning

confidence: 99%

See 1 more Smart Citation

GDC-0349 inhibits non-small cell lung cancer cell growth

Han

Zhao

et al. 2020

Cell Death Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…25 In non-small cell lung cancer, CircRNABIRC6 promotes tumor progression of by acting as a sponge of microRNA-145. 26 CircSAMSAP1 promotes the tumor growth of colorectal cancer through miR-328-5p/E2F1 axis. 27 Our study revealed that plasma circ_0004771 has stable cyclic structure, which provides the possibility of being a tumor biomarker.…”

Section: Introductionmentioning

confidence: 99%

<p>Comprehensive Assessment of Plasma Circ_0004771 as a Novel Diagnostic and Dynamic Monitoring Biomarker in Gastric Cancer</p>

Yan

Kong

Qin

et al. 2020

OTT

View full text Add to dashboard Cite

Due to the lack of specific and sensitive detection indicators, most patients with GC are already in the advanced stage at the time of diagnosis. Therefore, it is urgent to search for effective diagnostic biomarkers that can be applied in clinic. Materials and Methods: We screened out circ_0004771 through circRNA sequencing. Exonuclease digestion assay, agarose gel electrophoresis (AGE) and Sanger sequencing verified the potential of circ_0004771 being a biomarker. Additionally, we established quantitative real-time fluorescent polymerase chain reaction (qRT-PCR) to detect the expression level of circ_0004771 and evaluated the methodology. What's more, we collected plasma samples from 120 GC patients, 40 superficial gastritis patients, 20 postoperative GC patients, 20 postoperative recurrence patients and 120 healthy donors. We constructed the receiver operating characteristic curve (ROC) to appraise its diagnostic efficacy. Results: The expression level of circ_0004771 is up-regulated in GC tissues, which is consistent with circRNA sequencing result (P=0.0001). Circ_0004771 can serve as a promising biomarker because of its stable structure and longer half-life. Plasma circ_0004771 expression is markedly richer in GC patients than that in normal people (P<0.0001), and the area under the ROC (AUC) is 0.831 (95% CI: 0.779-0.883). The diagnostic efficacy of circ_0004771 is higher than that of CEA (AUC=0.747, 95% CI: 0.686-0.808) and CA199 (AUC=0.508, 95% CI: 0.433-0.583). Higher diagnostic efficacy can be achieved by combination diagnosis for distinguishing GC patients from normal people (AUC=0.864). Besides, the expression level of circ_0004771 can distinguish GC patients from gastritis patients (AUC=0.845, 95% CI: 0.772-0.917). The plasma circ_0004771 expression in GC patients decreased to normal after surgery (P<0.0001). In addition, plasma circ_0004771 expression increased again in patients with postoperative recurrence. Conclusion: Plasma circ_0004771 is differentially expressed in GC patients, postoperative GC patients and patients with recurrence, suggesting that plasma circ_0004771 can be used as a novel diagnostic and dynamic monitoring biomarker in GC.

show abstract

“…For example, circRGNEF promotes the progression of bladder cancer through the regulation of miR-548/KIF2C axis [20]. In non-small cell lung cancer, CircRNABIRC6 promotes tumor progression of by acting as a sponge of microRNA-145 [21]. CircSAMSAP1 promotes the tumor growth of colorectal cancer through miR-328-5p/E2F1 axis [22].…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Assessment of Plasma-Derived circ_0004771 as a Potential Biomarker in Tracking the Progression of Gastric Cancer

Kong

Qin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Due to the lack of specific and sensitive detection indicators, most patients with gastric cancer (GC) are already in the advanced stage at the time of diagnosis, resulting in a higher mortality. Therefore, it is urgent to search for effective diagnostic biomarkers with high specificity that can be applied in clinic. Methods: We screened out circ_0004771 through circRNA sequencing performed on three pairs of GC tissues and corresponding paracancerous tissues. Both exonuclease digestion assay, agarose gel electrophoresis (AGE) and sanger sequencing verified the potential of circ_0004771 being a biomarker. Additionally, we established quantitative real-time fluorescent Polymerase Chain Reaction (qRT-PCR) to detect the expression level of circ_0004771 and evaluated the methodology. What’s more, we collected plasma samples from GC patients, precancerous patients and gastritis patients, and we constructed the receiver operating characteristic curve (ROC) to appraise its diagnostic efficacy. Meanwhile, we collected the clinicopathological data of the patients to analyze the relationship between the expression level of circ_0004771 and the pathological parameters of the patients. Results: The expression level of circ_0004771 is up-regulated both in GC tissues and cells compared to normal controls. Circ_0004771 can be served as a promising biomarker because of its stable cyclic structure and longer half-life. The expression level of plasma circ_0004771 can distinguish between GC patients and precancerous patients, GC patients and gastritis patients. The diagnostic efficiency of circ_0004771 is higher than that of CEA and CA199. Higher diagnostic efficiency can be achieved in combination diagnosis. The expression level of plasma circ_0004771 in GC patients decreased after surgery, which can track the recovery condition of patients. Besides, the downstream regulatory forecast indicates that circ_0004771 may act as miRNA sponge to regulate the progression of GC.Conclusion: Plasma circ_0004771 can be served as a less invasive tumor biomarker with high diagnostic values.

show abstract

CircRNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145

Cited by 43 publications

References 28 publications

GDC-0349 inhibits non-small cell lung cancer cell growth

GDC-0349 inhibits non-small cell lung cancer cell growth

<p>Comprehensive Assessment of Plasma Circ_0004771 as a Novel Diagnostic and Dynamic Monitoring Biomarker in Gastric Cancer</p>

Comprehensive Assessment of Plasma-Derived circ_0004771 as a Potential Biomarker in Tracking the Progression of Gastric Cancer

Contact Info

Product

Resources

About